The Administrators of the Tulane Educational Fund

Elizabeth Bray Norton

John D Clements

Robert F Garry

Bruce Alan Bunnell

Suzanne L Tomchuck

The invention provides compositions and methods for reducing symptoms of inflammation by administering therapeutically effective amounts of (a) (1) enterotoxicheat labile detoxified toxin A subunit that interferes with the function of ADP-ribosylation factor and inhibits ADP-ribosylation, or (2) A1 subunit that interferes with the function of ADP-ribosylation factor and inhibits ADP-ribosylation, or both (1) and (2), and (b) a carrier that causes internalization of the A subunit or A1 subunit, or both, into cells.

Mutated e. coli enterotoxins as anti-inflammatory agents

Episomally transfected primary mesenchymal stem cells (MSC) express a polypeptide consisting of an antigenic polypeptide (e.g., one or more polypeptides) relating to a pathogen (e.g., one or more virus, bacterium, or parasite). The antigenic polypeptide can have the amino acid sequence of a natural polypeptide from the pathogen or an amino acid sequence differing from the natural sequence by one or more conservative amino acid substitutions. Uses and method for treating or preventing infections with episomally transfected primary MSC also are described.

Growing community of inventors

New Orleans, LA, United States of America

Elizabeth Bray Norton